These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34465496)

  • 1. Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update.
    Fischer B; Robinson T; Bullen C; Curran V; Jutras-Aswad D; Medina-Mora ME; Pacula RL; Rehm J; Room R; van den Brink W; Hall W
    Int J Drug Policy; 2022 Jan; 99():103381. PubMed ID: 34465496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.
    Fischer B; Russell C; Sabioni P; van den Brink W; Le Foll B; Hall W; Rehm J; Room R
    Am J Public Health; 2017 Aug; 107(8):e1-e12. PubMed ID: 28644037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower Risk Cannabis use Guidelines for Canada (LRCUG): a narrative review of evidence and recommendations.
    Fischer B; Jeffries V; Hall W; Room R; Goldner E; Rehm J
    Can J Public Health; 2011; 102(5):324-7. PubMed ID: 22032094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand.
    Fischer B; Daldegan-Bueno D; Bell R; Boden JM; Bullen C; Farrell M; Hall W; Newcombe D
    Public Health Pract (Oxf); 2020 Nov; 1():100046. PubMed ID: 36101675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Lower-Risk Cannabis Use Guidelines' (LRCUG) recommendations: How are Canadian cannabis users complying?
    Lee CR; Lee A; Goodman S; Hammond D; Fischer B
    Prev Med Rep; 2020 Dec; 20():101187. PubMed ID: 33083205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No. 367-2019 Canadian Guideline for Physical Activity throughout Pregnancy.
    Mottola MF; Davenport MH; Ruchat SM; Davies GA; Poitras V; Gray C; Jaramillo Garcia A; Barrowman N; Adamo KB; Duggan M; Barakat R; Chilibeck P; Fleming K; Forte M; Korolnek J; Nagpal T; Slater L; Stirling D; Zehr L
    J Obstet Gynaecol Can; 2018 Nov; 40(11):1528-1537. PubMed ID: 30297272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introducing the evidence-based population health tool of the Lower-Risk Cannabis Use Guidelines to Brazil.
    Fischer B; Malta M; Messas G; Ribeiro M
    Braz J Psychiatry; 2019; 41(6):550-555. PubMed ID: 31116260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging adult perceptions of higher-risk cannabis consumption behaviours.
    McMahon I; Harris-Lane LM; Donnan J; Bishop L; Harris N
    Harm Reduct J; 2023 Sep; 20(1):127. PubMed ID: 37679733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for Reducing the Risk of Cannabis Use-Related Adverse Psychosis Outcomes: A Public Mental Health-Oriented Evidence Review.
    Fischer B; Hall W; Fidalgo TM; Hoch E; Foll BL; Medina-Mora ME; Reimer J; Tibbo PG; Jutras-Aswad D
    J Dual Diagn; 2023; 19(2-3):71-96. PubMed ID: 37450645
    [No Abstract]   [Full Text] [Related]  

  • 12. Routes of administration for cannabis use - basic prevalence and related health outcomes: A scoping review and synthesis.
    Russell C; Rueda S; Room R; Tyndall M; Fischer B
    Int J Drug Policy; 2018 Feb; 52():87-96. PubMed ID: 29277082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health.
    Matheson J; Le Foll B
    Front Psychiatry; 2020; 11():591979. PubMed ID: 33173527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis knowledge and implications for health: Considerations regarding the legalization of non-medical cannabis.
    Zamengo L; Frison G; Zwitser G; Salomone A; Freeman TP
    Med Sci Law; 2020 Oct; 60(4):309-314. PubMed ID: 32600171
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.